Galapagos NV (GLPGF PINK) stock market data APIs
$34.9892
0(0%)
as of November 13, 2026
Try our APIs with
free plan!
Galapagos NV Financial Data Overview
Price chart is built with
Anychart
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Prev. Close
34.9892
Open
34.9892
High
34.9892
Low
34.9892
52 wk Range
26.24-35.15
Market Cap
2 316 M
P/E Ratio
3.3413
Shares Outstanding
65 897 K
Revenue
991 M
EPS
0.035
Beta
0.012
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galapagos NV data using free add-ons & libraries
Get Galapagos NV Fundamental Data
Galapagos NV Fundamental data includes:
- Net Revenue: 991 M
- EBITDA: 569 M
- Earnings Per Share: 10
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-10
- EPS/Forecast: -0.43
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galapagos NV News
New
Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update
Lakefront Biotherapeutics Gamgertamig poster accepted for presentation at the 2026 ASH1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B...
Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London
Lakefront Biotherapeutics Mechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 202...
Is Lakefront Biotherapeutics (ENXTAM:LKFT) Cheap Given Its Earnings Today?
Lakefront Biotherapeutics has climbed in the short term, yet a longer stretch of weak returns still hangs over the chart and puts fresh focus on what investors are paying for its earnings today. With ...
Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?
Lakefront Biotherapeutics - Sponsored ADR (LKFT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, LKFT's 50-day simple moving ...
Get Galapagos NV fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.